News

Ravi Agrawal, trustee of Ravi Agrawal Trust, released a pledge on 6,910 equity shares of Ajanta Pharma Limited on August 14, 2026, citing business financing as the reason, according to a regulatory filing with the BSE and National Stock Exchange. Aditya Birla Capital Limited was the lender, and Barclays Securities (India) Private Limited acted as the depositary participant.

Ravi Agrawal, a promoter of Ajanta Pharma Limited, has released a pledge on 54,796 equity shares of the company, citing Excess Pledge as the reason. The release involved multiple transactions between August 6 and August 12, 2026, with lenders including Deutsche Investments India Pvt Ltd, Bajaj Finance Limited, INFINA FINANCE LIMITED, and Tata Capital Limited, facilitated through Barclays Securities (India) Private Limited.

Ajanta Pharma announced that the Board of Directors of the Company at its meeting held on 30 July 2026, inter alia, have recommended the First Interim dividend of Rs 32 per equity Share (i.e. 1600%) , subject to the approval of the shareholders.

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2026.

Ajanta Pharma announced that the 47th Annual General Meeting(AGM) of the company will be held on 16 July 2026.